Edmund Williams
Psychiatry · San Antonio, TXNPI 1457345423
Payments from drug & device makers
Across 796 payments — averaging $178.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$104K
- Otsuka America Pharmaceutical, Inc.$12K
- Supernus Pharmaceuticals, Inc.$9K
- Tris Pharma Inc$5K
- Johnson & Johnson$4K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $7K from 33 others
What the payments were for
- Consulting fees$7201%
- Speaking & faculty fees$124,27787%
- Travel & lodging$3,1982%
- Food & beverage$13,99610%
- Education$1070%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,318 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 45 | $32,654 |
| VraylarCariprazine Hcl | 20 | $32,393 |
| FanaptIloperidone | 11 | $26,821 |
| RexultiBrexpiprazole | 11 | $18,772 |
| Lisdexamfetamine Dimesylate | 57 | $12,009 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,478 |
| AzstarysSerdexmethylphen/Dexmethylphen | 11 | $4,426 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 46 | $2,742 |
| Estazolam | 13 | $1,995 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 17 | $1,388 |
| Bupropion XlBupropion Hcl | 46 | $1,298 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 29 | $1,164 |
| Aripiprazole | 30 | $1,114 |
| Methylphenidate Hcl | 28 | $891 |
| Eszopiclone | 13 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $409 | $37,13256 claims |
| AbbVieVraylar | $104,297 | $32,39320 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $362 | $26,82111 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $11,892 | $18,77211 claims |
| Corium, LLCAzstarys | $108 | $4,42611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in San Antonio
- Thomas WeissSan Antonio$1.1M
- Jason MillerSan Antonio$869K
- Nathan JohnstonSan Antonio$435K
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.